Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | ELANE | P08246 | 1/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | STAT3 | P40763 | 5/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Scandoside SCHEMBL307654 | 1.00 | L3MBTL1 (0.61) | L3MBTL1MAPTELANEPTPN1MEN1 | |
| Scandoside SCHEMBL29682452 | 1.00 | L3MBTL1 (0.61) | L3MBTL1MAPTELANEPTPN1MEN1 | |
| SCHEMBL29425962 | 0.92 | L3MBTL1 (0.53) | L3MBTL1MAPTELANEPTPN1MEN1 | |
| SCHEMBL31179906 | 0.89 | ELANE (0.60) | L3MBTL1MAPTELANEPTPN1MEN1 | |
| SCHEMBL29425898 | 0.88 | ELANE (0.65) | L3MBTL1MAPTELANEPTPN1MEN1 | |
| SCHEMBL29425927 | 0.88 | ELANE (0.65) | L3MBTL1MAPTELANEPTPN1MEN1 | |
| SCHEMBL20572206 | 0.88 | ELANE (0.65) | L3MBTL1MAPTELANEPTPN1MEN1 | |
| SCHEMBL29896779 | 0.88 | ELANE (0.65) | L3MBTL1MAPTELANEPTPN1MEN1 | |
| Asperulosidic Acid SCHEMBL29459346 | 0.88 | MAPT (0.52) | L3MBTL1MAPTELANEPTPN1MEN1 | |
| Asperulosidic Acid SCHEMBL422107 | 0.88 | MAPT (0.52) | L3MBTL1MAPTELANEPTPN1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069649-A1 | COMPOSITION COMPRISING FERMENTED MORINDA CITRIFOLIA EXTRACT HAVING OSTEOARTHRITIS ALLEVIATION EFFECT | NSTBIO CO., LTD. (KR) | 2026-03-12 | — | — | US | claimed |
| CN-115245533-B | Application of Nanshan flower root extract in treating pulmonary fibrosis | 中国医学科学院药物研究所 | 2023-07-28 | — | — | CN | claimed |
| US-11628195-B2 | Method for preparing iridoid-rich noni fruit extract or fraction thereof, method for preparing immune-enhancing active material-rich noni fruit extract or fraction thereof and use of noni fruit extract or fraction thereof | COSMAX NBT, INC. (KR) | 2023-04-18 | — | — | US | claimed |
| US-20220408777-A1 | FOOD COMPOSITION FOR PREVENTING AND AMELIORATING DIABETES COMPRISING FERMENTED NONI AND METHOD FOR PREPARING SAME | NSTBIO. CO., LTD. (KR) | 2022-12-29 | — | — | US | claimed |
| WO-2022228095-A1 | APPLICATION OF PRISMATOMERIS CONNATA Y. Z. RUAN ROOT EXTRACT IN PREPARATION OF MEDICINE FOR TREATING PULMONARY FIBROSIS | 中国医学科学院药物研究所 | 2022-11-03 | — | — | WO | claimed |
| CN-115245533-A | Application of south mountain flower root extract in pulmonary fibrosis treatment | 中国医学科学院药物研究所 | 2022-10-28 | — | — | CN | claimed |
| US-20220080018-A1 | METHOD FOR PREPARING IRIDOID-RICH NONI FRUIT EXTRACT OR FRACTION THEREOF, METHOD FOR PREPARING IMMUNE-ENHANCING ACTIVE MATERIAL-RICH NONI FRUIT EXTRACT OR FRACTION THEREOF AND USE OF NONI FRUIT EXTRACT OR FRACTION THEREOF | COSMAX NBT, INC. (KR) | 2022-03-17 | — | — | US | claimed |
| US-20260069649-A1 | COMPOSITION COMPRISING FERMENTED MORINDA CITRIFOLIA EXTRACT HAVING OSTEOARTHRITIS ALLEVIATION EFFECT | NSTBIO CO., LTD. (KR) | 2026-03-12 | — | — | US | disclosed |
| EP-4702037-A1 | METHOD OF PRODUCING IRIDOIDS | Nicoventures Trading Limited (GB) | 2026-03-04 | — | — | EP | disclosed |
| US-12318424-B2 | Composition for enhancing exercise performance and fatigue recovery, containing fermented ripen noni, coconut sugar and muscovado sugar as active ingredients | ATOMY OROT CO., LTD. (KR) | 2025-06-03 | — | — | US | disclosed |
| US-12318423-B2 | Composition for enhancing exercise performance and fatigue recovery, containing fermented ripen noni, coconut sugar and muscovado sugar as active ingredients | ATOMY OROT CO., LTD. (KR) | 2025-06-03 | — | — | US | disclosed |
| CN-119908983-A | Application of gardenia pistil tissue in activation energy, protection, repair and aging resistance | 嘉药学校财团法人嘉南药理大学 | 2025-05-02 | — | — | CN | disclosed |
| CN-119837789-A | Application of gardenia in moisturizing, anti-inflammation, brightening, anti-wrinkle and anti-aging | 嘉药学校财团法人嘉南药理大学 | 2025-04-18 | — | — | CN | disclosed |
| CN-114680331-A | Food composition, pharmaceutical composition, quasi-pharmaceutical composition, feed composition and preparation method thereof | 艾多美股份有限公司 | 2022-07-01 | — | — | CN | disclosed |
| US-20220202893-A1 | COMPOSITION FOR STRESS RELIEF CONTAINING FERMENTED RIPEN NONI AND CALAMANSI EXTRACT SUGAR AS ACTIVE INGREDIENTS | NSTBIO CO., LTD. (KR) | 2022-06-30 | — | — | US | disclosed |
| US-11369628-B2 | Cranberry-derived compositions for potentiating antibiotic efficacy against bacterial persistence | UNIVERSITY OF RHODE ISLAND BOARD OF TRUSTEES (US) | 2022-06-28 | — | — | US | disclosed |
| WO-2022108343-A1 | COMPOSITION FOR HANGOVER RELIEF COMPRISING NONI FRUIT EXTRACT OR FRACTION THEREOF AND USE THEREOF | 코스맥스엔비티 주식회사 | 2022-05-27 | — | — | WO | disclosed |
| CN-114468279-A | Noni pomace enzyme and preparation method thereof | 中国热带农业科学院香料饮料研究所 | 2022-05-13 | — | — | CN | disclosed |
| US-20220080018-A1 | METHOD FOR PREPARING IRIDOID-RICH NONI FRUIT EXTRACT OR FRACTION THEREOF, METHOD FOR PREPARING IMMUNE-ENHANCING ACTIVE MATERIAL-RICH NONI FRUIT EXTRACT OR FRACTION THEREOF AND USE OF NONI FRUIT EXTRACT OR FRACTION THEREOF | COSMAX NBT, INC. (KR) | 2022-03-17 | — | — | US | disclosed |
| EP-3409766-B1 | AN ESTERASE THAT IS CAPABLE OF CONVERTING IRIDOIDS AND SECO-IRIDOIDS | N ZYME BIOTEC GMBH (DE) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260069649-A1 | COMPOSITION COMPRISING FERMENTED MORINDA CITRIFOLIA EXTRACT HAVING OSTEOARTHRITIS ALLEVIATION EFFECT | ACMSD, ALDOA, MAFG | L3MBTL1 4545/4885MAPT 600/4885ELANE 4302/4885 |
| US-11369628-B2 | Cranberry-derived compositions for potentiating antibiotic efficacy against bacterial persistence | LGALS1, GALE, ENGASE | L3MBTL1 2099/4885MAPT 3908/4885ELANE 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.